Point: Performance of HSP 90 Inhibitor As Initial Therapy In Multiple Myeloma: Tanespimycin Trademark Details

This mark is dead with a status of Abandoned - No Statement of Use Filed. The last case file activity for this mark occured 11 years ago on Monday, September 10, 2012, according to the United State Patent & Trademark Office
Word Mark Point: Performance of Hsp 90 Inhibitor as Initial Therapy in Multiple Myeloma: Tanespimycin
Status Dead 606 — Abandoned - No Statement of Use Filed

Current Owner

Bristol-Myers Squibb Company of New York, NY

View all trademarks for Bristol-Myers Squibb Company
Other Trademarks for Bristol-Myers Squibb Company
Serial Number 77795564
Status Date Monday, September 10, 2012
Filing Date Monday, September 10, 2012
Attorney Marilyn F. Kelly

Correspondent

Marilyn F. Kelly
Bristol-Myers Squibb Company
Trademark Department
345 Park Avenue
New York NY 10154

Case File Statements

Disclaimer with Predetermined Text "Performance of Hsp 90 Inhibitor as Initial Therapy in Multiple Myeloma Tanespimycin"
Goods & Services Medical and scientific research, namely, conducting clinical trials and clinical studies relating to pharmaceutical preparations for human use

Classifications

International Class Codes
042 — Class 42 includes mainly services provided by persons, individually or collectively, in relation to the theoretical and practical aspects of complex fields of activities; such services are provided by members of professions such as chemists, physicists, engineers, computer programmers, etc.
U.S. Class Codes 100, 101
Status 6 — Active
Status Date Thursday, August 6, 2009
Primary Code 042

You must be signed in to print.

Once signed in, look for the PDF button.